LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Home・Lista de Ações・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Fechado

SetorSaúde

65.44 -1.15

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

65.2

Máximo

67.18

Indicadores-chave
By Trading Economics
Rendimento	24M -167M
Vendas	40M 195M
EPS	-0.84
Margem de lucro	-85.626
Funcionários	834
EBITDA	75M -105M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+62.24% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	163M 14B
Abertura anterior	66.59
Fecho anterior	65.44

Sentimento de Notícias

By Acuity

100%

320 / 344 Ranking em Healthcare

Bridgebio Pharma Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de mai. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

31 de mai. de 2026, 23:36 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

31 de mai. de 2026, 23:36 UTC

Conversa de Mercado

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

31 de mai. de 2026, 23:36 UTC

Conversa de Mercado

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

31 de mai. de 2026, 22:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

29 de mai. de 2026, 23:08 UTC

Aquisições, Fusões, Aquisições de Empresas

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 de mai. de 2026, 23:06 UTC

Aquisições, Fusões, Aquisições de Empresas

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 de mai. de 2026, 20:53 UTC

Ganhos

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

29 de mai. de 2026, 20:33 UTC

Conversa de Mercado

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 de mai. de 2026, 20:11 UTC

Ganhos

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 de mai. de 2026, 19:47 UTC

Ganhos

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 de mai. de 2026, 19:36 UTC

Conversa de Mercado

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 de mai. de 2026, 19:34 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

29 de mai. de 2026, 19:34 UTC

Conversa de Mercado

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 de mai. de 2026, 19:22 UTC

Conversa de Mercado

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 de mai. de 2026, 19:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 de mai. de 2026, 18:19 UTC

Conversa de Mercado

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 de mai. de 2026, 18:12 UTC

Aquisições, Fusões, Aquisições de Empresas

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 de mai. de 2026, 18:11 UTC

Conversa de Mercado

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 de mai. de 2026, 18:10 UTC

Conversa de Mercado

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 de mai. de 2026, 17:55 UTC

Ganhos

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 de mai. de 2026, 17:55 UTC

Conversa de Mercado

NEAR Protocol Nearly Doubles in May -- Market Talk

29 de mai. de 2026, 17:38 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 de mai. de 2026, 17:00 UTC

Ganhos

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

29 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

29 de mai. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

29 de mai. de 2026, 16:02 UTC

Conversa de Mercado

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 de mai. de 2026, 15:55 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Bridgebio Pharma Inc Previsão

Preço-alvo

By TipRanks

62.24% parte superior

Previsão para 12 meses

Média 107.5 USD 62.24%

Máximo 157 USD

Mínimo 82 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para Bridgebio Pharma Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

18 ratings

Comprar

Manter

Vender

Com base em 18 analistas que deram avaliações de ações para Bridgebio Pharma Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

320 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.